PrEP

July 25th 2024

Adherence and efficacy were both higher in patients with HIV who took twice-yearly lenacapavir compared to those on oral preexposure prophylaxis medication.

July 21st 2024

The shift is intended to maintain uninterrupted access to PrEP, crucial for preventing HIV, and highlights the ongoing efforts to end the HIV epidemic by improving public health outcomes.

January 11th 2024

Variations and conditions included in existing state bills, however, limit the effectiveness of this approach.

December 18th 2023

The study, which consists of 3 trials, will continue with oral PrEP regimens; however, the vaccination trials have stopped due to the unlikely chance of the vaccine showing efficacy.